KEGG DRUG

Search results

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY	Disease ID
1	SATRALIZUMAB (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[3] 11, 13, 86
2	Satralizumab (120 mg/PFS with NSD) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
3	Satralizumab (120 mg/vial) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
4	Satralizumab (120mg/vial) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
5	Satralizumab (Genetical Recombination)	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 86
6	Satralizumab (r-INN) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
7	Satralizumab (RO5333787/Enspryng /SA237) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
8	Satralizumab (RO5333787/Enspryng/SA237) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
9	Satralizumab (RO5333787/SA237) (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13
10	Satralizumab 120 mg (Synonym: Satralizumab (genetical recombination) (JAN))	[1] Satralizumab	[1] D11079 (Name: Satralizumab (genetical recombination) (JAN))	[1] IL6R 💬	[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬	[1] 13